- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06534437
MEN1703 (SEL24) para tratar linfoma não-Hodgkin agressivo de células B recidivante ou refratário (JASPIS-01) (JASPIS-01)
Um ensaio clínico aberto de fase 2 de MEN1703 como monoterapia e em combinação com glofitamabe em pacientes com linfoma não-Hodgkin agressivo de células B recidivante ou refratário
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time:
- Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma
- Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study consists of 3 parts, to investigate MEN1703 (Dapolsertib hydrochloride) in combination with glofitamab in patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) or MEN1703 alone in patients who have exhausted all standard treatment options (group 2).
Part 1 (safety run-in) and Part 2 (enrichment): patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive either 150 mg or 125 mg of MEN1703 along with glofitamab. Patients who have exhausted all standard treatment options (group 2) will receive 125 mg of MEN1703 as a single-agent.
Part 3 (optional randomized comparison): Patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody therapy will be randomized to receive either MEN1703 (Dapolsertib hydrochloride) at a dose selected from part 2 in combination with glofitamab or glofitamab alone.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Head of Clinical Operations
- Número de telefone: +48 123140200
- E-mail: clinicaltrials@ryvu.com
Locais de estudo
-
-
-
Barcelona, Espanha, 08035
- Recrutamento
- Hospital Universitari Vall D Hebron
-
Investigador principal:
- Crisitna Garcia Herce, MD PhD
-
Madrid, Espanha, 28033
- Recrutamento
- MD Anderson Cancer Center
-
Investigador principal:
- Adolfo De La Fuente Burguera, MD PhD
-
Madrid, Espanha
- Recrutamento
- Hospital Universitario Puerta de Hierro Majadahonda
-
Investigador principal:
- Mariano Provencio Pulla, MD PhD
-
Madrid, Espanha, 28027
- Recrutamento
- Clinica Universidad De Navarra
-
Investigador principal:
- Miguel Angel Canales Albendea, MD PhD
-
Murcia, Espanha, 30120
- Ainda não está recrutando
- Hospital Clínico Uni versitario Virgen de la Arrixaca
-
Investigador principal:
- Ignacio Espanol Morales, Dr
-
Pamplona, Espanha, 31008
- Recrutamento
- Clinica Universidad De Navarra
-
Investigador principal:
- Miguel Angel Canales Albendea, MD PhD
-
Pamplona, Espanha, 31008
- Recrutamento
- Hospital Universitario De Navarra
-
Investigador principal:
- Jose Maria Arguinano Perez, MD PhD
-
Salamanca, Espanha, 37007
- Recrutamento
- Hospital Universitario De Salamanca
-
Investigador principal:
- Norma Carmen Gutierrez, Prof.
-
Seville, Espanha, 41009
- Recrutamento
- Hospital Universitario Virgen De La Macarena
-
Investigador principal:
- Natalia Palazon, MD PhD
-
Zaragoza, Espanha
- Recrutamento
- Hospital Universitario Miguel Servet
-
Investigador principal:
- Araceli Rubio Martinez, MD PhD
-
-
-
-
-
Le Mans, França, 72037
- Recrutamento
- Centre Hospitalier Le Mans
-
Investigador principal:
- Kamel Laribi, MD PhD
-
Lille, França
- Recrutamento
- CHU de Lille - Hôpital Claude Huriez
-
Investigador principal:
- Franck Morschhauser, Prof.
-
Limoges, França, 87042
- Recrutamento
- CHU de Limoges - CHU Dupuytren
-
Investigador principal:
- Julie Abraham, MD PhD
-
Lyon, França, 69310
- Recrutamento
- Hospices Civils De Lyon - Hôpital Lyon Sud
-
Investigador principal:
- Herve Ghesquieres, Prof.
-
Montpellier, França, 34490
- Recrutamento
- CHU Montpellier - Hôpital Saint Eloi
-
Investigador principal:
- Guillaume Cartron, MD PhD
-
Paris, França, 75651
- Recrutamento
- APHP - Hôpital Pitié-Salpêtrière
-
Investigador principal:
- Sylvain Choquet, MD PhD
-
Pessac, França, 33600
- Recrutamento
- CHU de Bordeaux - Hôpital Haut-Lévêque
-
Investigador principal:
- Francois Xavier Gros, MD PhD
-
-
-
-
-
Biała Podlaska, Polônia
- Rescindido
- Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
-
Bydgoszcz, Polônia
- Recrutamento
- IN-VIVO Bydgoszcz Sp. z o.o.
-
Investigador principal:
- Jarosław Czyż, Prof.
-
Gdansk, Polônia
- Ainda não está recrutando
- Klinika Hematologii I Transplantologii Uck
-
Investigador principal:
- Jan Zaucha, Prof.
-
Gdynia, Polônia
- Recrutamento
- Szpitale Pomorskie Sp. z o.o.
-
Investigador principal:
- Adam Witkowski, MD PhD
-
Gliwice, Polônia
- Recrutamento
- Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy
-
Contato:
- Małgorzata Krawczyk-Kuliś, Prof.
-
Investigador principal:
- Małgorzata Krawczyk-Kuliś, Prof.
-
Katowice, Polônia
- Rescindido
- Pratia Hematologia Sp. z o.o.
-
Krakow, Polônia
- Recrutamento
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Investigador principal:
- Agnieszka Giza, MD PhD
-
Krakow, Polônia
- Recrutamento
- Pratia MCM Kraków
-
Contato:
- Wojciech Jurczak, Prof.
-
Investigador principal:
- Wojciech Jurczak, Prof.
-
Olsztyn, Polônia
- Recrutamento
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
-
Contato:
- Janusz Hałka, MD PhD
-
Investigador principal:
- Janusz Hałka, MD PhD
-
Skórzewo, Polônia
- Recrutamento
- Aidport Sp. z o.o.
-
Investigador principal:
- Michał Kwiatek, Dr
-
Torun, Polônia
- Recrutamento
- Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
-
Contato:
- Dominik Chraniuk, MD
-
Investigador principal:
- Dominik Chraniuk, MD
-
Warsaw, Polônia
- Rescindido
- Lux Med Onkologia Sp. z o.o.
-
Warsaw, Polônia
- Rescindido
- Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
-
-
-
-
-
Glasgow, Reino Unido
- Recrutamento
- Beatson West of Scotland Cancer Centre
-
Investigador principal:
- Mark Rafferty, Dr
-
Manchester, Reino Unido
- Recrutamento
- The Christie NHS Foundation Trust
-
Investigador principal:
- Kim Linton, Dr
-
Plymouth, Reino Unido
- Recrutamento
- Plymouth Hospitals NHS Trust
-
Investigador principal:
- David Burns, Dr
-
Sutton, Reino Unido
- Recrutamento
- The Royal Marsden Hospital
-
Investigador principal:
- David Cunningham, Dr
-
Tooting, Reino Unido
- Recrutamento
- St George's Hospital
-
Investigador principal:
- Ruth Pettengell, Dr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥18 years old
- Documented histological confirmation of aggressive B-cell non-Hodgkin lymphoma including DLBCL NOS and transformed indolent B-cell lymphoma
- Relapsed or refractory disease having received at least 2 prior lines of systemic treatment and, naïve to anti-CD3xCD20 bispecific antibody treatment (group 1) or exhausted all standard, available treatment options (group 2)
- At least 1 measurable site of disease based on computed tomography (CT) or positron emission tomography (PET)-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes.
- Availability of lymph node tissue at Screening (or archival sample) (part 2 participants only)
- Life expectancy of ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Adequate organ function at Screening
- Adequate hematologic function
Exclusion Criteria:
-
Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening.
-
Received anti-cancer treatments, including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy, or investigational drugs within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. Prior treatment with CAR-T cell or an anti-CD3xCD20 bispecific antibody therapy (permitted for Group 2 only), requires a wash out period of ≥4 weeks.
-
Concurrent participation in another therapeutic clinical study.
-
Ongoing clinically significant toxicity (for example, alopecia is not clinically significant) from any prior anti-cancer therapy that has not resolved to Grade 1 or less prior to the first dose of study drug.
-
Prior treatment with a PIM inhibitor.
-
Group 1 only: Any prior therapy with a bispecific antibody targeting CD3 and CD20.
-
Known risk of allergy to the study drugs, MEN1703 (group 1 and 2) or glofitamab (group 1) or their excipients
-
Contraindication to all uric acid lowering agents.
-
Major surgery within 1 month prior to first dose of study drug.
-
Hematopoietic stem cell transplant within 4 months prior to first dose of study drug.
-
Requires systemic immune-modulating therapy (regardless of dose) or has confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression.
-
Exposed to live or live attenuated vaccine(s) within 4 weeks prior to signing the informed consent form (ICF).
-
Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection, except for documented Grade Common Terminology Criteria for Adverse Events (CTCAE) ≤2 infections with evidence of improvement or without evidence of worsening infection.
-
Known human immunodeficiency virus (HIV) infection
-
Current active liver disease from any cause
-
Ongoing drug-induced pneumonitis.
-
Ongoing inflammatory bowel disease.
-
Active known second malignancy
-
Received an agent known to be a sensitive CYP2D6 substrate or a CYP2D6 substrate with a narrow therapeutic range, a strong or moderate CYP2D6 inhibitor, or a BCRP inhibitor within 14 days or 5 half-lives (whichever is shorter), prior to the first dose of study drug.
-
Cardiac dysfunction is defined as myocardial infarction within 6 months of study entry, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.
-
Receiving treatment for active, ongoing thromboembolic event. Note: Does not apply to prophylactic treatment to prevent or avoid reoccurrence of a prior resolved event. To review with Medical Monitor where further risk assessment is needed.
-
History of serious ventricular arrhythmia (e.g., VT or VF, ≥3 beats in a row), or QT interval corrected for heart rate (QTc) ≥480 ms.
Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g., bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
-
Any disease, syndrome or condition which may significantly affect drug intake via oral route.
-
Planning to become pregnant or breastfeed during treatment and for 1 month after the last dose of study drug.
-
Any other prior or current medical condition, intercurrent illness, surgical history, physical or 12-lead electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MEN1703 + glofitamab
• Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will be given MEN1703 orally at a dose of 150 mg daily for 7 days or 125 mg daily for 14 days, in 21-day cycles for a maximum of 12 cycles, in combination with glofitamab administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (parts 1, 2, 3)). All participants will be administered 1,000 mg of obinutuzumab as an IV infusion on cycle 1 day 1. • Participants who have exhausted all standard treatment options (group 2) will receive MEN1703 as a single-agent, at a dose of 125 mg orally every-day for 14 consecutive days in consecutive 21-day treatment cycles, until progressive disease (parts 1 and 2). |
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Outros nomes:
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
|
Comparador Ativo: Gofitamab
Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive glofitamab as a single-agent administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (part 3). |
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 1: Incidence and severity of adverse events (AE)
Prazo: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Part 2 and Part 3: Complete response (CR) (group 1)
Prazo: 12 months
|
Assessed per Lugano Response Criteria for Malignant Lymphoma |
12 months
|
|
Part 2 and Part 3: Overall response rate (group 2)
Prazo: 12 months
|
Assessed as the number of patients who achieve a complete response (CR) or partial response (PR), per Lugano Response Criteria, divided by the total number of evaluable patients |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 2 and Part 3, Incidence and severity of AE
Prazo: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Maximum Plasma Concentration (Cmax)
Prazo: 12 months
|
Assessment of the peak plasma concentration (Cmax) |
12 months
|
|
Maximum Plasma Concentration (Tmax)
Prazo: 12 months
|
Assessment of the time to peak plasma concentration (Tmax) |
12 months
|
|
Area Under the Concentration Time-Curve (AUC)
Prazo: 12 months
|
Assessed of the area under the plasma concentration versus time curve (AUC) |
12 months
|
|
Impact of treatment on patient reported outcomes (PRO)
Prazo: 12 months
|
Assessed as changes in lymphoma symptoms, well-being, and general health status measured according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) consisting of 30 questions that assess five domains of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status/quality of life (GHS/QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All are scored from 0 to 100, with higher scores on the five domains and GHS/QoL being reflective of better health related (HR) QoL, and higher scores on the symptom scales and single items reflective of poor HRQoL. |
12 months
|
|
Impact of treatment on quality of life (QOL)
Prazo: 12 months
|
Assessed as changes in lymphoma symptoms and health related quality of life (HRQoL) as measured using the 15-item Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) including physical, social/family, emotional, and functional well-being and includes a lymphoma-specific subscale. The scale range is 0 to 60, with a higher score reflecting a better HRQoL. |
12 months
|
|
Overall survival (OS)
Prazo: 12 months
|
Assessed as the time from first treatment to death. |
12 months
|
|
Progression-free survival (PFS)
Prazo: 12 months
|
Assessed as time from the time from first treatment to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Response (DoR)
Prazo: 12 months
|
Assessed as the time from first response (CR or PR) to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Complete Response (DoCR)
Prazo: 12 months
|
Assessed as the time from first complete response (CR) to the first occurrence of disease progression or death. |
12 months
|
|
Time to response
Prazo: 12 months
|
Assessed as the time from the first treatment to the time of first response (CR or PR). |
12 months
|
|
Time to next treatment
Prazo: 12 months
|
Assessed as the time from the first treatment to the start date of the first therapy received after the participant has ended study treatment and received subsequent anti-lymphoma therapy. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Comportamento motor aberrante na demência
- Processos Patológicos
- Neoplasias
- Atributos da doença
- Doenças do sistema imunológico
- Sintomas Comportamentais
- Neoplasias por Tipo Histológico
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma
- Condições Patológicas, Sinais e Sintomas
- Comportamento
- Doenças hemic e linfáticas
- Comportamento social
- Recorrência
- Linfoma Não-Hodgkin
- Agressão
- Glofitamab
Outros números de identificação do estudo
- JASPIS-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .